The Use of Antiepileptics in Migraine Prophylaxis

Headache

Volumn 56, Issue 3, 2016, Pages 603-615

  Bagnato, Francesca ^a   Good, Janine ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

acetazolamide; divalproex sodium; gabapentin; migraine; prophylaxis; topiramate

Indexed keywords

ACETAZOLAMIDE; ANTICONVULSIVE AGENT; CARBAMAZEPINE; CARISBAMATE; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PERAMPANEL; SODIUM CHANNEL BLOCKING AGENT; TOPIRAMATE; VALPROATE SEMISODIUM; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

AGRANULOCYTOSIS; ALOPECIA; ANION GAP; APLASTIC ANEMIA; ARTICLE; ASTHENIA; BLURRED VISION; BREAST DISEASE; CLINICAL PRACTICE; CONSTIPATION; CRYSTALLURIA; DIARRHEA; DIZZINESS; DROWSINESS; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG MECHANISM; DYSPEPSIA; ELECTROLYTE DISTURBANCE; FATIGUE; HAIR LOSS; HEADACHE; HEMATURIA; HOT FLUSH; HUMAN; HYPERAMMONEMIA; HYPERNATREMIA; HYPEROSMOLALITY; HYPERTHERMIA; HYPERURICEMIA; HYPOCALCEMIA; HYPOCITRATURIA; HYPOKALEMIA; HYPOTENSION; LEUKOPENIA; LOSS OF APPETITE; MAXIMUM TOLERATED DOSE; MEMORY DISORDER; MENTAL DISEASE; METABOLIC ACIDOSIS; MIGRAINE; MIGRAINE WITHOUT AURA; MIOSIS; MONOTHERAPY; MOOD DISORDER; MULTICENTER STUDY (TOPIC); MYOCLONUS; NAUSEA; NAUSEA AND VOMITING; NEPHROLITHIASIS; NEUROGENIC INFLAMMATION; PANCREATITIS; PARESTHESIA; PATHOGENESIS; PATHOPHYSIOLOGY; PREGNANCY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATION DEPRESSION; SEDATION; SIDE EFFECT; SOMNOLENCE; SPREADING CORTICAL DEPRESSION; TACHYCARDIA; THROMBOCYTOPENIA; THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME; TREMOR; VOMITING; WEIGHT GAIN; MIGRAINE DISORDERS;

ANTICONVULSANTS; HUMANS; MIGRAINE DISORDERS;

EID: 84959499919     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/head.12781     Document Type: Article

References (81)

1. Lipton RB, Silberstein SD., Episodic and chronic migraine headache: Breaking down barriers to optimal treatment and prevention. Headache. 2015; 55 (Suppl 2): 103-122.
2. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 2013; 33: 629-808.
3. Silberstein SD, Goadsby PJ., Migraine headache: Preventive treatment. Cephalalgia. 2002; 22: 491-512.
4. Sicuteri F., Prophylactic treatment of migraine by means of lysergic acid derivates. Triangle. 1963; 67: 116-125.
5. Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C., Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults. Neurology. 2012; 78: 1337-1345.
6. Tajti, J, Pardutz A, Vamos E, et al., Migraine is a neuronal disease. J Neural Transm. 2011; 118: 511-524.
7. Rapoport A, Edmeads J., Migraine-The evolution of our knowledge. Arch Neurol. 2000; 57: 1221-1223.
8. Edvinsson L, Villalon CM, VanDenBrink A., Basic mechanisms of migraine and its acute treatment. Pharmacol Ther. 2012; 136: 319-333.
9. Goadsby PJ, Charbi AR, Andreou AP, Akerman S, Holland PR., Neurobiology of migraine. Neuroscience. 2009; 161: 327-341.
10. Moskowitz MA., Genes, proteases, cortical spreading depression and migraine: Impact on pathophysiology and treatment. Funct Neurol. 2007; 22: 133-136.
11. Moskowitz MA., Molecular mechanism of migraine. Rinsho Shinkeigaku. 2008; 48: 798.
12. Gasperini C, Sutherland HG, Griffiths LR., Studies on the pathophysiology and genetic basis of migraine. Curr Genomics. 2013; 14: 300-315.
13. Silberstein SD, for the US Headache Consortium. Practice-parameter: Evidence-based guidelines for migraine headache (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000; 55; 754-762.
14. Johannessen CU., Mechanisms of action of valproate: A commentatory. Neurochem Int. 2000; 37: 103-110.
15. Galletti F, Cupini LM, Corbelli I, Calabresi P, Sarchielli P., Pathophysiological basis of migraine prophylaxis. Prog Neurobiol. 2009; 89: 176-192.
16. Cutrer FM, Limnroth V, Moskowitz MA., Possible mechanisms of valproate in migraine prophylaxis. Cephalalgia. 1977; 17: 93-99.
17. Sørensen KV., Valproate: A new drug in migraine prophylaxis. Acta Neurol Scand. 1988; 78: 346-348.
18. Hering R, Kuritzky A., Sodium valproate in the prophylactic treatment of migraine: A double-blind study versus placebo. Cephalalgia. 1992; 12: 81-84.
19. Jensen R, Brinck T, Olesen J., Sodium valproate has a prophylactic effect in migraine without aura: A triple-blind, placebo-controlled crossover study. Neurology. 1994; 44: 647-651.
20. Mathew NT, Saper JR, Silberstein SD, et al., Migraine prophylaxis with divalproex. Arch Neurol. 1995; 52: 281-186.
21. Klapper J., Divalproex sodium in migraine prophylaxis: A dose-controlled study. Cephalalgia. 1997; 17: 103-108.
22. Kaniecki RG., A comparison of divalproex with propranolol and placebo for the profilaxis of migraine without aura. Arch Neurol. 1997; 54: 1141-1145.
23. Chiossi L, Negro A, Capi M, Lionetto L, Martelletti P., Sodium channel antagonists for the treatment of migraine. Expert Opin Pharmacother. 2014; 15: 1697-1706.
24. Line M, Mulleners WM, Chronicle EP, McCrory DC., Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev. 2013;Issue 6. Art. No.:CD010611.
25. Freitag FG, Collins SD, Carlson HA, et al., A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology. 2002; 58: 1652-1659.
26. Peterlin BL, Ward TN, Levin M., Anti-epileptic drugs in migraine prevention. Headache Pain. 2005; 16: 18-36.
27. Silberstein SD, Collins SD., Safety of divalproex sodium in migraine prophylaxis: An open-label, long-term study: Long-term safety of Depakote in Headache Prophylaxis Study Group. Headache. 1999; 39: 633-643.
28. Anderson GO, Ritland S., Life threatening intoxication with sodium valproate. Clin Toxicol. 1995; 33: 279-284.
29. Dupuis RE, Lichtman SN, Pollack GM., Acute valproic acid overdose. Clinical course and pharmacokinetic disposition of valproic acid and metabolites. Drug Saf. 1990; 5: 65-71.
30. Harden CL, Hopp J, Ting TY, et al., Practice Parameter update: Management issues for women with epilepsy-Focus on pregnancy (an evidence based review): Teratogene Neuroreport sis and perinatal outcomes. Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology. 2009; 73: 133-141.
31. Costa C, Martella G, Picconi B, et al., Multiple mechanisms underlying the neuroprotective effects of antiepileptic drugs against in vitro ischemia. Stroke. 2006; 37: 1319-1326.
32. White HS, Brown SD, Woodhead JH, Skeen GA, Wolf HH., Topiramate modulates GABA-evoked currents in murine cortical neurons by a non benzodiazepine mechanism. Epilepsia. 2000; 41:S 17-20.
33. Akerman S, Goadsby PJ., Topiramate inhibits cortical spreading depression in rat and cat: Impact in migraine aura. Neuroreport. 2005; 16: 1383-1387.
34. Di Clemente L, Puledda F, Biasiotta A, et al., Topiramate modulates habituation in migraine: evidences from nociceptive responses elicited by laser evoked potentials. J Headache Pain. 2013; 14: 25.
35. Ben-Menachem E, Sander JW, Stefan H, Schwalen S, Schäuble B., Topiramate monotherapy in the treatment of newly or recently diagnosed epilepsy. Clin Ther. 2008; 30: 1180-1195.
36. Silberstein SD, Ben-Menachem E, Shank RP, Wiegand F., Topiramate monotherapy in epilepsy and migraine prevention. Clin Ther. 2005; 27: 154-165.
37. Storey JR, Calder CS, Hart DE, Potter DL., Topiramate in migraine prevention: A double-blind, placebo-controlled study. Headache. 2001; 41: 968-975.
38. Shaygannejad V, Janghorbani M, Ghorbani A, Ashtary F, Zakizade N, Nasr V., Comparison of the effect of topiramate and sodium valproate in migraine prevention: A randomized blinded crossover study. Headache. 2006; 46: 642-648.
39. Gupta P, Singh S, Goyal V, Shukla G, Behari M., Low-dose topiramate versus lamotrigine in migraine prophylaxis (the Lotolamp study). Headache. 2007; 47: 402-412.
40. Ashtari F, Shaygannejad V, Akbari M., A double-blind, randomized trial of low-dose topiramate vs propranolol in migraine prophylaxis. Acta Neurol Scand. 2008; 18: 301-305.
41. Brandes JL, Saper JR, Diamond M, et al., Topiramate for migraine prevention: A randomized controlled trial. JAMA. 2004; 291: 965-973.
42. Diener HC, Tfelt-Hansen P, Dahlöf C, et al., Topiramate in migraine prophylaxis: Results from a placebo-controlled trial with propranolol as an active control. J Neurol. 2004; 251: 943-950.
43. Dodick DW, Freitag F, Banks J, et al., Topiramate versus amitriptyline in migraine prevention: A 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group non inferiority trial in adult migraineurs. Clin Ther. 2009; 31: 542-559.
44. Keskinbora K, Aydinli I., A double-blind randomized controlled trial of topiramate and amitriptyline either alone or in combination for the prevention of migraine. Clin Neurol Neurosurg. 2008; 110: 979-984.
45. Mei D, Capuano A, Vollono C, et al., Topiramate in migraine prophylaxis: A randomised double-blind versus placebo study. Neurol Sci. 2004; 25: 245-250.
46. Silberstein SD, Neto W, Schmitt J, Jacobs D,; MIGR-001 Study Group. Topiramate in migraine prevention: Results of a large controlled trial. Arch Neurol. 2004; 61: 490-495.
47. Millan-Guerrero RO, Isais-Millan R, Barreto-Vizcaíno S, et al., Subcutaneous histamine versus topiramate in migraine prophylaxis: A double-blind study. Eur Neurol. 2008; 59: 237-242.
48. Linde M, Mulleners WM, Chronicle EP, McCrory DC., Topiramate for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev. 2013;Issue 6. Art. No.:CD010610.
49. Ashtari F, Shaygannejad V, Akbari M., A double-blind, randomized trial of low-dose topiramate vs propranolol in migraine prophylaxis. Acta Neurol Scand. 2008; 118: 301-305.
50. Luo N, Di W, Zhang A, et al., A randomized, one-year clinical trial comparing the efficacy of topiramate, flunarizine, and a combination of flunarizine and topiramate in migraine prophylaxis. Pain Med. 2012; 13: 80-86.
51. Varkey E, Cider Å, Carlsson J, Linde M., Exercise as migraine prophylaxis: A randomized study using relaxation and topiramate as controls. Cephalalgia. 2011; 31: 1428-1438.
52. Wile D., Diuretics: A review. Ann Clin Biochem. 2012; 49: 419-431.
53. Vega D, Maalouf NM, Sakhaee K., Increased propensity for calcium phosphate kidney stones with topiramate use. Expert Opin Drug Saf. 2007; 6: 547-557.
54. Mirza NS, Marson AG, Pirmohamed M., Effect of topiramate on acid-base balance: Extent, mechanism and effects. Br J Clin Pharmacol. 2009; 68: 655-661.
55. Abtahi MA, Abtahi SH, Fazel F, et al., Topiramate and the vision: a systematic review. Clin Ophthalmol. 2012; 6: 117-131.
56. Senthil S, Garudadri C, Rao HB, Maheshwari R., Bilateral simultaneous acute angle closure caused by sulphonamide derivatives: A case series. Indian J Ophthalmol. 2010; 58: 248-252.
57. Ohman I, Sabers A, de Flon P, Luef G, Tomson T., Pharmacokinetics of topiramate during pregnancy. Epilepsy Res. 2009; 87: 124-129.
58. Ohman I, Vitols S, Luef G, Söderfeldt B, Tomson T., Topiramate kinetics during delivery, lactation, and in the neonate: Preliminary observations. Epilepsia. 2002; 43: 1157-1160.
59. Westin AA, Nakken KO, Johannessen SI, Reimers A, Lillestølen KM, Brodtkorb E., Serum concentration/dose ratio of topiramate during pregnancy. Epilepsia. 2009; 50: 480-485.
60. Rompel H, Bauermeister PW., Aetiology of migraine and prevention with carbamazepine (Tegretol): Results of a double-blind, cross-over study. S Afr Med J. 1970; 44: 75-80.
61. Zhang Y, Shao G, Zhang W, et al., Gabapentin inhibits central sensitization during migraine. Neural Regen Res. 2013; 8: 3003-3012.
62. Di Trapani G, Mei D, Marra C, Mazza S, Capuano A., Gabapentin in the prophylaxis of migraine: A double-blind randomized placebo-controlled study. Clin Ther. 2000; 151: 145-148.
63. Mathew NT, Rapoport A, Saper J, et al., Efficacy of gabapentin in migraine prophylaxis. Headache. 2001; 41: 11928.
64. Jimenez-Hernandez MD, Torrecillas Narvaez MD, Friera Acebal G., Effectiveness and safety of gabapentin in the preventive treatment of migraine. Rev Neurol. 2002; 35: 603-606.
65. Silberstein S, Goode-Sellers S, Twomey C, Sajers J, Ascher J., Randomized, double-blind, placebo-controlled, phase II trial of gabapentin enacarbil for migraine prophylaxis. Cephalalgia. 2013; 33: 101-111.
66. Mulleners WM, McCrory D, Linde M., Antiepileptics in migraine prophylaxis: An updated Cochrane review. Cephalalgia. 2015; 35: 51-62.
67. Sacco S, Rasura M, Cao M, Bozzao A, Carolei A., CADASIL presenting as status migrainosus and persisting aura without infarction. J Headache Pain. 2009; 10: 51-53.
68. Simone R, Marano E, Stasio E, Bonuso S, Fiorillo C, Bonavita V., Acetazolamide efficacy and tolerability in migraine with aura: a pilot study. Headache. 2005; 45: 385-386.
69. De Simone R, Marano E, Di Stasio E, Bonuso S, Fiorillo C, Bonavita V., Acetazolamide efficacy and tolerability in migraine with aura: A pilot study. Headache. 2005; 4: 385-386.
70. Vahedi K, Taupin P, Djomby R, et al., Efficacy and tolerability of acetazolamide in migraine prophylaxis: A randomized placebo-controlled trial. J Neurol. 2002; 249: 20611.
71. Steiner TJ, Findley LJ, Yuen AW., Lamotrigine versus placebo in the prophylaxis of migraine with and without aura. Cephalalgia. 1997; 17: 109-112.
72. Silberstein SD, Saper J, Berenson F, Somogyi M, McCague MA, D'Souza JD., Oxcarbazepine in migraine headache: A double-blind, randomized, placebo-controlled study. Neurology. 2008; 70: 548-555.
73. Linde M, Mulleners WM, Chronicle EP, McCrory DC., Antiepileptics other than gabapentin, pregabalin, topiramate, and valproate for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev. 2013; 6: CD010608.
74. Beran RG, Spira PJ,. Levetiracetam in chronic daily headache: a double blind, randomized, placebo controlled study. The Australian-Keppra Headache Trial (AUS-KHT) cephalgia. 2011; 5: 530-536.
75. Verma A, Srivastava D, Kumar A, Singh V., Lecetiracetam in migraine profilaxis: A randomized placebo-controlled study in a rural medical institute in Northen India. Clin Neuropharmacol. 2013; 193-197.
76. Drake ME Jr, Greathouse NI, Renner JB, Armentbright AD., Open-label zonisamide for refractory migraine. Clin Neuropharmacol. 2004; 27: 278-280.
77. Ashkenazi A, Benlifer A, Korenblit J, Silberstein SD., Zonisamide for migraine prophylaxis in refractory patients. Cephalalgia. 2006; 26: 1199-1202.
78. Bermejo PE, Dorado R., Zonisamide for migraine prophylaxis in patients refractory to topiramate. Clin Neuropharmacol. 2009; 32: 103-106.
79. Villani V, Ciuffoli A, Prosperini L, Sette G., Zonisamide for migraine prophylaxis in topiramate-intolerant patients: An observational study. Headache. 2011; 51: 287-291.
80. Mohammadianinejad SE, Abbasi V, Sajedi SA, et al., Zonisamide versus topiramate in migraine prophylaxis: A double-blind randomized clinical trial. Clin Neuropharmacol. 2011; 34: 174-177.
81. Shulze-Bonhage A., Perampanel for epilepsy with partial-onset seizures: A pharmaco-kinetic and pharmacodynamic evaluation. Expert Opin Drug Metab Toxicol. 2015; 11: 1329-1337.